Please assess the completion status of the following clinical trial:

Trial Title: Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient must be at least 21 days after stem cell infusion~* Clinical status must allow tapering of steroids to \< 0.5mg/kg prednisone or other steroid equivalent~Exclusion Criteria:~* Patients who have developed viral infection or reactivation will be ineligible for prophylactic infusions of VSTs~* Active acute GVHD grades II-IV~* Uncontrolled relapse of malignancy~* Infusion of ATG or alemtuzumab within 2 weeks of VST infusion. Additionally, in patients who received alemtuzumab as part of their conditioning regimen, alemtuzumab levels will be collected in the second week following stem cell infusion. The level must be less than, or equal to, 0.15 prior to infusion of VSTs. In patients with level greater than 0.15, alemtuzumab levels can be checked serially until a level ≤ 0.15 is obtained. They would become eligible for prophylactic VST infusion at that point if there is still no evidence of viral infection at that time.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Viral Specific T-cells (VSTs) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).